Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.

Molecular diagnosis & therapy - 1 Jun 2015

Li Yonghong, Bare Lance A, Bender Richard A, Sninsky John J, Wilson Leslie S, Devlin James J, Waldman Frederic M

Abstract excerpt

OBJECTIVE: To determine whether a next-generation sequencing (NGS) panel of 34 cancer-associated genes would cost-effectively aid in the treatment selection for patients with metastatic melanoma, compared with a single-site BRAF V600 mutation test. METHODS: A decision model was developed to estim...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Decision Support Techniques
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Economic

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Quality-Adjusted Life Years

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 25926090
DOI: 10.1007/s40291-015-0140-9
PMCID: PMC4469775

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25926090-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.PMID 25926090Read ↗

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.Semantic proximity Read ↗

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced MelanomaSemantic proximity Read ↗

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.Semantic proximity Read ↗

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Semantic proximity Read ↗

Guidance of Sentinel Lymph Node Biopsy Decisions In Patients With T1–T2 Melanoma Using Gene Expression ProfilingSemantic proximity Read ↗

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.